The design of conditional gene expression systems restricted to given tissues or cellular types is an important issue of gene therapy. Systems based on the targeting of molecules characteristic of the pathological state of tissues would be of interest. We have developed a synthetic transcription factor by fusing a single chain antibody (scFv) directed against p53 with the bacterial tetracycline repressor as a DNA binding domain. This hybrid protein binds to p53 and can interact with a synthetic promoter containing tetracycline-operator sequences. Gene expression can now be speci®cally achieved in tumor cells harboring an endogenous mutant p53 but not in a wild-type p53 containing tumor cell line or in a non-transformed cell line. Thus, a functional transactivator centered on single chain antibodies can be expressed intracellularly and induce gene expression in a scFv-mediated speci®c manner. This novel class of transcriptional transactivators could be referred as trabodies' for transcription-activating-antibodies. The trabodies technology could be useful to any cell type in which a disease related protein could be the target of speci®c antibodies.
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The possibility to restrain the function of a therapeutic gene in a given cell type or tissue may be a critical issue in the ®eld of gene therapy. Viral and non viral vectors that would carry such a therapeutic gene may be engineered to target a speci®c cell type. Thus, ligands have been introduced into the envelope of viral vectors to bind their cognate receptors speci®cally expressed at the surface of the target cells (Nilson et al., 1996) . Speci®city could also be achieved at the level of gene expression. Most eorts have focused at the transcriptional level through the use of tissue speci®c promoters derived from genes, which have a restricted expression pattern (Ayoubi and Van De Ven 1996) . Another approach would be to design a restricted gene expression system based on the targeting of diseaserelated molecules whose expression and functional activity is a landmark of the pathological state. For instance, oncogenes and tumor suppressor genes represent speci®c markers of cancer cells through overexpression, mutation or deletion. It would be advantageous to use such marker molecules as the basis of a restricted gene expression system. We decided to design a speci®c gene expression system by choosing p53 mutant as a target model. p53 represents the most frequent genetic alteration in human cancers (Hainaut et al., 1997) . Ninety percent of these alterations are missense mutations, which for the most part induce a conformational change leading to a stabilization of the protein, preventing DNA binding and subsequent transcriptional activation (Hainaut et al., 1997; Harris, 1993) . Such missense mutations occur within the core of p53, leaving the amino-terminal transactivation domain intact. If this transactivation domain could be recruited to activate a synthetic promoter, one could reasonably hope to achieve p53 mutant speci®c gene expression. Such an approach is reminiscent of the double hybrid system, originally described in yeast and which has also been applied to mammalian cells (Fields and Sternglanz, 1994; Luo et al., 1997) . In this approach, it is absolutely required to use a known ligand for the target to be recruited. As p53 form tetramers via a carboxy-terminal domain, one could envision to use this oligomerization domain. In addition, p53 speci®c partners could be the basis for de®ning domains that would serve as ligands as well. However, ligands speci®c for a chosen target are not always available. Thus, we tried to develop a system centred on a type of universal ligand. Monoclonal antibodies or their fragments (Fab', Fv) would in principle represent such ligands. They can display high speci®city with excellent anities. Single chain Fv antibody fragment (scFv) in which the variable light and heavy chains are connected via a¯exible linker and expressed as a single polypeptide represent the smallest functional fragment that maintain binding and speci®city (Huston et al., 1988; Glockshuber et al., 1990) . Several applications of intracellular expression of scFv's have been reported, de®ning them as a potential new class of therapeutic reagents . HIV viral proteins such as tat, rev, gp120 (Pilkington et al., 1996; Chen et al., 1996) , oncogene products such as Ras (Biocca et al., 1994; Cochet et al., 1998) , erbB-2 (Schmidt et al., 1996) , EGF receptors (Jannot et al., 1996) and other membrane receptors such as IL2-R have been the targets of scFv's which inhibited their function sometimes by redirecting their localization in another cellular compartment (Persic et al., 1997a) . Several examples of chimeric proteins joining scFv's to other functional moieties such as toxins (Wels et al., 1995) , dimerization domains (de Kruif and Logtenberg, 1996; Hu et al., 1996) , TCR CD3 z-chain (Moritz and Groner, 1995) , protamine have also been described. These chimeras rely on the scFv to work as a speci®c ligand. Here, we assign transcriptional activation as a novel application for scFv based chimeric molecules, which is exempli®ed by the fusion between an anti-p53 scFv and the bacterial tetracycline repressor as a DNA binding motif (Figure 1) . A single chain Fv fragment was derived from the anti-p53 PAb421 monoclonal antibody (Caron de Fromentel et al. accompanying manuscript). PAb421 recognizes an epitope localized in the carboxy-terminal domain of p53 (Arai et al., 1986) . Thus, recruitment of an endogenous mutant p53 by the pAb421-derived scFv should not interfere with its transactivation domain, which is located within the amino-terminal moiety. Although pAb421 cannot discriminate between wildtype and mutant p53, we assumed that the increased half-life of mutant p53 compared to wild-type p53 (Reihsaus et al., 1990) would nevertheless result in a mutant p53 speci®c eect. The 421-ScFv was cloned by phage display and was shown to bind to p53 (Caron de Fromentel et al. accompanying manuscript; Figure 2 ). We chose the tetracycline repressor (TetR) as a speci®c DNA binding unit for the following reasons. The DNA operator sequences recognized by tetR are 17 base pair long rendering very unlikely the existence of such sequences within the human genome. In addition, the TetR has been successfully used as a fusion protein with the VP16 activation domain, constituting the basis of a pharmacologically regulated gene expression system in vitro and in vivo (Gossen and Bujard, 1992; S-labelled in vitro from pCDNA3 derived vectors (TnT kit, Promega). Equimolar amounts of the translated products were then incubated with either 1 mg of unlabeled full length p53 (1 ± 393, black boxes) or 0.8 mg of unlabeled deleted p53 (p53D320 ± 393, grey boxes) produced and puri®ed from Baculovirus nuclear extracts in 10 mM Tris.HCI (pH 8.0), 1 mM EDTA, 150 mM NaCl, 1% NP-40. The reaction samples were immunoprecipitated with DO-1 using Immunoprecipitin (Gibco ± BRL) as a carrier, washed and eluted. The immunoprecipitates were analyzed via polyacrylamide gel electrophoresis and quanti®ed with an Instant Imager (Packard Instruments). Quanti®cation of the amount of the immunoprecipitated complexes obtained with full length p53 (black boxes) or a truncated p53 deleted in its carboxy-terminal (1 ± 320) (grey boxes) are reported as a percentage with respect to the labelled input. 1: Naked pAb421 ScFv, 2: ScFv/TetR, 3: NLS-ScFv/TetR, 4: ScFv-NLS/TetR, 5: (320-393)/TetR Figure 3 Gel retardation assays between the tetR-chimeras and a tet operator containing ds DNA. A synthetic double-stranded oligonucleotide corresponding to the tetracycline operator sequence was labeled with 32 P-ATP and T4 polynucleotide kinase. The (320 ± 393)/TetR and ScFv/TetR and ScFv/TetR were produced unlabelled in vitro as above-described. The operator DNA (10 710 M) and the translated products were incubated for 15 min at room temperature in 10 mM Tris.HCl (pH 7.4), 10 mM MgCl 2 , 10 mM KCl, 6 mM beta-mercaptoethanol, 0.1 mM EDTA, 0.5 mg/ml BSA, 10 78 M competitor AP2 DNA. The samples were resolved on a 5% acrylamide gel. When required, tetracycline (10 mM) or puri®ed p53 (100 ng) were pre-incubated with the translated products before adding the labeled operator DNA. (320 ± 393)/TetR and ScFv/TetR were incubated with a 20 base pair DNA element containing the tet operator (lanes b,e). Before adding the tet operator DNA, the two chimeras were incubated with tetracycline (lanes c,f) or wild-type p53 (lanes d,g) Kistner et al., 1996) . The 421-ScFv was positioned as an amino-terminal fusion with the TetR (ScFv/TetR, Figure 1a ). Fusion molecules containing scFv's have been realized in this orientation and allow proper recognition of the antigen (Kistner et al., 1996) . In addition, the fused moiety may stabilize the scFv, substituting to some extent to the immunoglobulin light chain constant region (Mhashilkar et al., 1995) . A linker, VSV-Hinge, including a ten aminoacid long peptide derived from the upper hinge region of mouse IgG3 (Pack and Pluckthun, 1992) and an immunodetectable tag consisting of a 11 amino-acid long peptide derived from the carboxy-teminal domain of the Vesicular Stomatites Virus glycoprotein (Kreis, 1986) was inserted between the scFv and the TetR. In addition, a nuclear localization signal derived from the SV40 Large T antigen (NLS) (Goldfarb et al., 1986) was included at the amino-terminal or carboxyterminal end of the scFv in the chimera (NLS-ScFv/ TetR and ScFv-NLS/TetR, Figure 1b and c) . The p53 oligomerization domain corresponding to amino-acids 320 ± 393 was used as a positive control ((320 ± 393)/ TetR, Figure 1d ) as this domain was previously shown to properly fold and oligomerize with p53 when expressed intracellularly alone or fused to the DNA binding domain of the Gal4 yeast transactivator (Shaulian et al., 1992; Da Costa et al., 1996) .
Co-immunoprecipitation assays were performed to determine whether the fused scFv maintained its ability to recognize p53 when expressed as a chimera. The various chimeras and the naked scFv as a control were 35 S-labelled in an in vitro synthesis using rabbit reticulocyte lysates. They were incubated with either unlabelled full-length wild-type p53 or with an unlabelled carboxy-terminally truncated p53 (p53D320 ± 393) which served as a negative control since it lacks the p53 oligomerization domain and the pAb421 epitope. The complexes were immunoprecipitated with DO1, a monoclonal antibody directed against the p53 amino-terminal domain which binds the full-length and the truncated p53 proteins equally well. The amount of co-immunoprecipitated labeled material was evaluated following gel electrophoresis (Figure 2) . The scFv's present in the various chimeras were able to speci®cally recognize p53 via its carboxyterminal epitope. The fusion molecules bearing the NLS seemed more ecient in binding p53 which may be due to a better folding of the scFv. However, the ScFv/TetR proteins appeared to be less ecient in associating with p53 than (320 ± 393)/TetR suggesting that the oligomerization domain displays a stronger anity for p53 than the 421-ScFv.
The functionality of the TetR as a speci®c DNA binding motif within the chimeras was tested in a gel retardation assay. 32 P-labelled Tet operator DNA was incubated with unlabelled ScFv/TetR and (320 ± 393)/ TetR produced from reticulocyte lysates. Retarded bands were obtained with both chimeras (Figure 3b and e). These signals were TetR-dependent as they were displaced upon the addition of tetracycline (Figure 3c and f) . Incubating puri®ed wild-type p53 with the chimeras before adding the operator DNA did not prevent the formation of the retarded complex (Figure 3d and g ), suggesting a lack of steric hindrance Figure 4 Nuclear staining of the ScFv/TetR fusion protein in H1299 cells. A rabbit polyclonal antibody was raised against four dierent ScFvs puri®ed from E. coli periplasmic fractions. This polyclonal was shown to recognize separate ScFvs as well as total IgGs (Cochet et al., 1998) . Upon plating on culture chambers (Lab-Tek, Nunc), H1299 cells were transfected with control or expression vector for scFv/TetR. Twenty-four hours later, cells were ®xed in PBS/formaldehyde 4%, permeabilized in PBS/Triton X-100 0.2% then incubated with the anti-ScFv antibody in Power Block buer (BioGenex) to be revealed with a secondary antirabbit IgG serum coupled to FITC (Jackson Immunoresearch). Upon transfection of the ScFv/TetR expression vector in H1299 cells, a nuclear localization was observed in every transfected cell, as revealed with an anti-scFv polyclonal antibody between bound p53 and TetR. Similar data were obtained with the NLS containing chimeras (data not shown).
As we had evidence that both moieties, the scFv and the TetR were functional within the chimeras, we pursued the evaluation of these hybrid proteins following expression in mammalian cells. Following transient transfection in H1299, a p53 null lung carcinoma cell line, protein expression and localization were monitored using a rabbit anti-ScFv polyclonal Figure 5 Transactivating functions of the two tetR-chimeras. Transient transfection assays were performed using Lipofectamine (Gibco-BRL) and a DNA compacting Histone H1-derived peptide (Byk et al., 1995) . pUHC13-6 bearing the luciferase reporter gene under the control of a tetracycline-dependent promoter (Gossen and Bujard, 1992) was used in each assay. The luciferase activity was quanti®ed 48 h after transfection (Luciferase Assay System, Promega). Data are expressed as the mean of three independent experiments. (a) Transient transfections in H358 (p53 null) cell line. Expression vectors for wt or mutant p53 (500 ng), for (320 ± 393)TetR or ScFv/TetR (250 ng) and for the appropriate luciferase reporter gene (250 ng) were introduced in H358. The basal signal has been set to one arbitrary unit. (b) Transient transfections in NIH3T3, H460 and H322 cell lines. Expression vectors for (320 ± 393)/TetR or ScFv/TetR (250 ng) and the luciferase reporter gene (250 ng) were introduced in the various cell lines. The basal signal has been set to one arbitrary unit, independently in each cell line antiserum. Strong nuclear¯uorescence was observed with ScFv/TetR (Figure 4 ) although no obvious potential NLS sequences seem to be present within the construct. A similar nuclear localization has been observed for Tet/VP16 which does not contain any consensus NLS sequences as well (Kistner et al., 1996) . Western blotting revealed the expression of ScFv/TetR at the proper apparent molecular weight (data not shown). ScFv/TetR can therefore localize into the nucleus, a prerequisite for its ecient function as a transcriptional transactivator. The NLS containing chimeras displayed a strong nuclear localization as well (data not shown).
The ability of the chimeric transcription factors to mediate mutant p53 gene expression was assessed in transient transfection assays. A luciferase reporter gene was placed under the control of a minimal tk promoter downstream from tetracycline operator DNA sequences. This reporter plasmid was cotransfected with expression vectors for ScFv/TetR or (320-393)/TetR without or with expression vectors for wild-type p53, His273, Gly281 or His175 p53 mutants in H358, a p53 null lung tumor cell line (Figure 5a ). Wild-type p53 repressed the tet/tk promoter, an activity known to be exerted by wild-type p53 on several promoters (Ginsberg et al., 1991) . This repression was somewhat relieved by the two chimeras to achieve, however, a level of gene expression close to the basal level. Coexpression of any of the chimeras with the His273 and Gly281 p53 mutant but not with the His175 mutant led to enhanced gene expression. This latter result was expected as it had been reported that the His175 transactivation domain was non functional (Fields and Jang, 1990) . Identical results were obtained with the NLS containing ScFv/TetR molecules (data not shown). Reminiscent of the coimmunoprecipitation assays, ScFv/TetR was about half as ecient as (320 ± 393)/TetR, suggesting a lower binding of this fusion molecule to p53. As these results were obtained with exogenously produced p53 proteins, we next examined the functionality of the chimeric factors in a non transformed cell line and in tumor cell lines expressing endogenous wild-type or mutant p53. The reporter gene containing vector and the ScFv/TetR or (320 ± 393)/TetR expression vectors were cotransfected in the non transformed NIH3T3 (wt/wt) cell line and in the transformed H460 (wt/wt) and H322 (7/Leu248) cell lines. Transcriptional transactivation was mediated by ScFv/TetR and (320 ± 393)/TetR in H322 but not in NIH3T3 or H460 cell lines (Figure 5b ). As the two chimeras were correctly expressed in the three cell lines, these results suggest that the endogenous p53 mutant expressed in H322 was speci®cally recruited to mediate this eect.
The SV40 Large T antigen has been previously used as a fusion to the Gal4 DNA binding domain to trap exogenously expressed mutant p53 to direct speci®c gene expression (Da Costa et al., 1996) . We have provided evidence that single chain antibodies can also be utilized as the basis of functional entities mediating tumor speci®c gene expression, using a similar p53-based model. Speci®c gene expression was not only observed with mutant p53 introduced in a p53 null cell line but also in the H322 cell line expressing an endogenous mutant p53. This new class of synthetic molecules could be referred as`trabodies' for transcription activating antibodies. Necessary technical improvements would have to be achieved beforè trabodies' could be incorporated in gene therapy applications. Comparisons between the results obtained with ScFv/TetR and (320 ± 393)/TetR indicate that stronger transactivating abilities could probably be achieved by utilizing a scFv derived from a monoclonal antibody with higher anity. Indeed, pAb421 is a monoclonal antibody that poorly binds p53. In addition, the choice of alternate linkers between the scFv and TetR may provide a more functional transactivator. The incorporation of NLS turned out not to be necessary as the ScFv/TetR chimera was localized within the nucleus. Finally, the relative positioning of the tet operator sequences within the promoter could probably be optimized to achieve a higher level of transactivation. The possibility to use tetracycline or tetracycline analogs to switch gene expression on and o (Kistner et al., 1996) could provide a clinically relevant tool.
Due to the universality of ScFvs to serve as ligands, the tumor speci®c gene expression system that we have developed with an anti-p53 scFv could be adapted to other molecular targets relevant of pathological situations. ScFvs may also provide a speci®city advantage over naturally occurring ligands which may associate with additional, undesired cellular partners (such as SV40 large T antigen which binds Rb family members in addition to p53). Ideally these pathology-associated targets should possess a functional transactivation domain and would thus be particularly suitable for antiviral strategies since viruses often encode transcriptional transactivators. One can also envision implementing the`trabodies' technology in targeting proteins lacking transactivating domains. A system could be developed in which the target would bridge two scFv fusion proteins. The ®rst fusion would tether an anti-target scFv to the TetR domain while the second chimera would connect a second anti-target scFv to an activation domain such as the VP16 domain. The use of scFv libraries associated to phage display screening technologies (Persic et al., 1997b) would permit the rapid development of the tools necessary to desigǹ trabodies'.
